Eisbach Bio

Eisbach and Cancer Focus Fund Announce $4.5m Investment to Support First-in-Human Phase 1/2 Trial of EIS-12656 for Refractory Advanced Solid Tumours

Eisbach is enabling the potential of synthetic lethality by developing novel compounds to exploit molecular vulnerabilities uniquely present in many hard-to-treat cancers 21 March 2024 -- Martinsried, Germany and Texas, US -- Eisbach Bio, a clinical-stage biotechnology company pioneering a new class of cancer medicines leveraging synthetic lethality to target specific proteins that are essential for...
Am Klopferspitz 19, 82152 Planegg, Germany

+49 89 21537900